---
title: "VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293923273.md"
description: "VERAXA Biotech recently announced that their bispecific antibody-drug conjugate (ADC) program, VXA-222, developed in collaboration with OmniAb, has progressed to the next phase at VERAXA. This significant advancement comes after the successful attainment of a crucial technical milestone. VXA-222 holds promise in the field of biotechnology and is set to revolutionize treatment strategies with its innovative approach. This development marks a milestone in the collaboration between VERAXA and OmniAb, highlighting their commitment to advancing cutting-edge research in the biopharmaceutical industry."
datetime: "2026-07-27T11:02:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293923273.md)
  - [en](https://longbridge.com/en/news/293923273.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293923273.md)
generator: "portal-rs"
---

# VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb

VERAXA Biotech recently announced that their bispecific antibody-drug conjugate (ADC) program, VXA-222, developed in collaboration with OmniAb, has progressed to the next phase at VERAXA. This significant advancement comes after the successful attainment of a crucial technical milestone. VXA-222 holds promise in the field of biotechnology and is set to revolutionize treatment strategies with its innovative approach. This development marks a milestone in the collaboration between VERAXA and OmniAb, highlighting their commitment to advancing cutting-edge research in the biopharmaceutical industry.

### Related Stocks

- [VRXA.US](https://longbridge.com/en/quote/VRXA.US.md)
- [OABI.US](https://longbridge.com/en/quote/OABI.US.md)
- [OABIW.US](https://longbridge.com/en/quote/OABIW.US.md)

## Related News & Research

- [OmniAb to present at Nasdaq/LD Micro Summit Series](https://longbridge.com/en/news/297041629.md)
- [VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program Beyond Discovery Phase](https://longbridge.com/en/news/296932909.md)
- [Veraxa Biotech reports positive in vitro proof-of-concept for antibody-oligonucleotide conjugate candidate with Secarna](https://longbridge.com/en/news/296781575.md)
- [VERAXA Biotech (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision](https://longbridge.com/en/news/296815081.md)
- [WuXi Biologics (Cayman) (SEHK:2269) Shares Climbed, So What Is Driving Attention Now?](https://longbridge.com/en/news/296943664.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**